1. Scrip

Korean Tagrisso Launch Builds On Extensive Local Data

 
• By Jung Won Shin

AstraZeneca's Tagrisso has debuted in South Korea, raising hopes and treatment options for certain types of lung cancer patients, but the product will face immediate local direct competition from Hanmi’s recently launched rival olmutinib.

SEOUL - South Korea has become the fifth market for AstraZeneca PLC's first-in-class lung cancer drug Tagrisso (osimertinib) after the US, Europe, Japan and Israel, following approval by the Ministry of Food and Drug Safety for EGFR T790M mutation-positive progressive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have undergone EGFR-TKI therapy.

AstraZeneca Korea said the drug had been launched without reimbursement initially, but that it is seeking to apply for national health insurance coverage. The approval was based on Phase II...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.